Pharmaceutical compositions based on Diclofenae

Details Pharmaceutical compositions based on Diclofenae Pharmaceutical compositions based on Diclofenae

2005-12-13

2005-12-13

Wilson, James O. (Department: 1623)

Drug, bio-affecting and body treating compositions

Inorganic active ingredient containing

Alkali metal or alkaline earth containing

C424S717000, C562S454000, C562S456000, C562S457000, C560S047000, C514S553000, C514S557000, C514S576000

Reexamination Certificate

active

06974595

ABSTRACT:
New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain in human patients higher Cmaxof the active principle and shorter Tmaxtogether with a lower coefficient of variation.

REFERENCES:
patent: 0 466 650 (1992-01-01), None
patent: 466650 (1992-01-01), None
Henry, D., et al; “Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis”; BMJ; vol. 312, pp. 1563-1566, (1996).
Walker, A.M.; “Quantitative studies of the risk of serious heptatic injury in persons using nonsteroidal antiinflammatory drugs”; Arthritis and Rheumatism, vol. 40, No. 2, pp. 201-208 (1997).
Gutthann, S.P., et al; “Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure”; Arch. Intern. Med., vol. 156, pp. 2433-2439, (1996).
Amidon, G.L., et al; “A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability”; Pharm. Research, vol. 12, No. 3, pp. 413-420, (1995).
Neuvonen, P.J., “The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac”; Br. J. Clin. Pharmac. vol. 31, pp. 263-266, (1991).
Neuvonen, P.J., et al; “Enhancement of drug absorption by antacids”; Clin. Pharmacokinet. 27 (2): pp. 120-128, (1994).
Neuvonen, P.J., et al; “Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids”; Eur. J. Clin. Pharmacol, 35: pp. 495-501, (1988).
Derendorf, H., et al; “Pharmacokinetics of diclofenac sodium after intramuscular administration in combination with triamcinolone acetate”; Eur. J. Clin. Pharmacol., 31:363-365 (1986).
Terhaag, B., et al; “Bioavailability of a new effervescent tablet of diclofenac”; Int. J. Clin. Pharmacol. Ther., 38:546:551 (2000).
Lotsch, J., et al.; “Population pharmacokinetics of fast release oral diclofenac in healthy volunteers: relation to pharmacodynamics in an experimental pain model”; Pharmaceutical Research, vol. 17, No. 1, pp. 77-84, (2000).
Marzo, A., et al; “Pharmacokinetics of Diclofenac after oral administration of its potassium salt in sachet an tabled formulations”; Arzneim. Forsch., 50:43-47 (2000).
Reiner, V., et al; “Increased absorption rate of diclofenac from fast acting formulations containing its potassium salt”; Arzneim. Forsch., 51:885-890 (2001).
Brogden, R.N., et al; “Diclofenac sodium: A review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying orgin”; Drugs, 20: pp. 24-48, (1980).
Macia, M.A., et al; “Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks”; Int. J. Clin Pharmacol. Ther., 33:333-339 (1995).
Bettmi, R., et al; “Swelling force development as a result of hydrate formation in diclofenac sodium or nitrofurantoin tablets”; S.T.P. Pharma Sciences 10 (4) pp. 335-339, (2000).
Henrikson, P.A., et al; Absorption and effect of diclofenac sodium after surgical removal of a ower wisdom tooth; Curr. Ther. Res., 31:30-26 (1982).
Degen, P.H., et al; “Pharmacokinetics of diclofenac and five metabolites after single doses in healthy volunteers and after repeated doses in patients”; Xenobiotica, 18:1449-1455 (1988).
Maggi, C.A., et al; “Comparative bioavailability of diclofenac hydroxyethylpyrrolidine vs diclofenac sodium in man”; Eur. J. Clin. Pharmacol., 38:207-208 (1990).
Mendes, G.B.B., et al; “Comparative bioavailability of two suspension formulations of potassium diclofenac in healthy male volunteers”; Int. J. Clin. Pharmacol. Thr., 32:131-135 (1994).
Crook, P.R., et al; “The pharmacokinetics of diclofenac sodium in patients with active rheumatoid disease”; Eur. J. Clin. Pharmacol., 21:331-334 (1982).
Willis, J.V., et al; “The pharmacokinetics of diclofenac sodium following intravenous and oral administration”; Eur. J. Clin. Pharmacol., 16:405-410 (1979).
Willis, J.V., et al; “The influence of food on the absorption of diclofenac after single and multiple oral doses”; Eur. J. Clin. Pharmacol., 19:33-37 (1981).
Riess, W., et al; “Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaen” Scand. J. Reumatol., Suppl. 22:17-29 (1978).
Physicians' Desk Reference; Novartis Pharmaceutical Corp., pp. 1830-1832 (2000).

Affiliated with

Also associated with

Rating

Pharmaceutical compositions based on Diclofenae does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical compositions based on Diclofenae, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions based on Diclofenae will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3506384